Introduction
Brain and central nervous system (CNS) tumors found in adolescents and young adults (AYA) are a distinct group of tumors that pose challenges not only to treatment but also to reporting. Overall, cancer that occurs in this age group is biologically distinct from those that occur in both younger and older age groups 1, 2 posing significant challenges for clinicians. The most commonly diagnosed histologies in AYA vary from those in both children age (0-14 years), and older adults (40+ years). 3, 4 Prognosis and expected survival also varies between younger and older adults, with those who are diagnosed with brain and CNS tumors at younger ages having significantly longer survival. Despite this survival advantage, recent analyses have reported that while cancer survival has been improving overall, AYA have not experienced these same increases in survival and in some cases may have worse survival than those cancers diagnosed in persons over age 40 years. 5 This report provides an in depth analyses of the epidemiology of brain and CNS tumors in adolescents and young adults in the United States (US), and is the first report to provide histology-specific statistics in this population for both malignant and non-malignant brain and other CNS tumors.
In 2006, the National Institutes of Health, the National Cancer Institute (NCI) and the LiveStrong Young Adult Alliance conducted a Progress Review Group to investigate AYA Oncology entitled Research and care imperatives for adolescents and young adults with cancer: A Report of the Adolescent and Young Adult Oncology Progress Review Group. This group established the standard age range for the AYA group as 15-39 years. This is the age range used by the Surveillance Epidemiology and End Results (SEER) program of the NCI, as well as in the 2015 CBTRUS Statistical Report. 3, 6 Brain tumors and other CNS tumors are less common in AYA than in older adults, but they have a higher incidence than brain tumors in children (age 0-14 years).
3 Non-malignant tumors are significantly more common in AYA than children (Average annual age adjusted incidence in age 15-39 years: 6.17 per 100,000; age 0-14 years: 0.79 per 100,000), while malignant tumors are slightly more common in those age 0-14 years (Average annual age adjusted incidence in 15-39 years old: 3.26 per 100,000; 0-14 years old: 3.73 per 100,000). While a rare cancer overall, brain and CNS tumors are among the most common cancers occurring in this age group (4.4% of all cancers in those age 15-39 years as compared to 32.4% in children age 0-14 years, and 2.2% of cancers in adults age 40+ years). 3, 4, 7 Malignant brain and CNS tumors are the 11 th most common cancer and the 3 rd most common cause of cancer death 7, 8 in the AYA population. Incidence rates of brain tumors overall as well as specific histologies vary significantly by age. It is, therefore, important to provide an accurate statistical assessment of brain and other CNS tumors in the adolescent and young adult population to better understand their impact on the US population and to serve as a reference for afflicted individuals, for researchers investigating new therapies and for clinicians treating patients.
Background
CBTRUS is a population-based site-specific registry in the US that works in partnership with a public cancer surveillance organization, the CDC's National Program of Central Registries (NPCR), and from which data are directly received under a special agreement. This agreement permits transfer of data through the NPCR Cancer Surveillance System (NPCR-CSS) Submission Specifications mechanism. CBTRUS researchers combine the NPCR data with data from the NCI SEER program 9 which was established for national cancer surveillance in the early 1970s. All data from NPCR and SEER originate from tumor registrars who adhere to the Uniform Data Standards (UDS) for malignant and non-malignant brain and CNS tumors as directed by the North American Association of Central Cancer Registries (NAACCR) (http://www. naaccr.org) and report these data to the central cancer registry in their state. Along with the UDS, there are quality control checks and a system for rating each central cancer registry to further insure that these data are reported as accurately and completely as possible. As a surveillance partner, CBTRUS can, therefore, report high quality data on brain and CNS tumors with histological specificity useful to the communities it serves. Its database represents the largest aggregation of populationbased data on the incidence of primary brain and CNS tumors in the US. Aggregate information on all cancers from all central cancer registries in the United States, including primary brain and CNS, is available in United States Cancer Statistics.
7,10
Technical Notes
Data Collection
CBTRUS contains incidence data from 51 independent central cancer registries (46 NPCR and 5 SEER registries), including 50 state cancer registries and the District of Columbia, representing 99.9% of the US population for the time period examined in this report (for 1 of 51 registries, data were available only from [2008] [2009] [2010] .
3 Please see The CBTRUS Statistical Report: Primary and Central Nervous System Tumors Diagnosed in the US in 2008-2012 for additional information about the way that these data are obtained and processed. 3 Incidence is a measure of newly diagnosed cases of a disease in a population. Crude incidence rates are calculated by dividing total number of new cases, by the overall population for the same time period. Age-adjusted incidence rates are calculated by generating crude rates by age group, and then summing these together based on a standard age distribution which adjusts for the effect of age distribution variation between different populations. Age-adjusted incidence rates per 100,000 for the entire US for selected other cancers were obtained from the US Cancer Statistics (USCS), 7 produced by the CDC and the NCI, via CDC Wide-ranging Online Data for Epidemiologic Research (WONDER), for the purpose of comparison with brain and CNS tumor incidence rates. This database includes both NPCR and SEER data and represents nearly 100% of the US population.
Survival information derived from active patient follow-up is not available in the data that CBTRUS receives from NPCR registries, so SEER data are used to generate these Tables. Survival data for malignant brain and CNS tumors were obtained from 18 SEER registries for the years 1995 to 2012. This dataset spanning 17 years currently provides population-based information for approximately 28% of the US population as of the US 2010 Census, 11, 12 and is a subset of the CBTRUS combined NPCR and SEER data used for the incidence calculations in this report.
Mortality data used in this report are from the National Center for Health Statistics and include deaths where primary brain or CNS tumor was listed as cause of death on the death certificate for all 50 states and the District of Columbia. Population data for each geographic region were obtained from the SEER program website 13 for the purpose of rate calculations.
Data Reporting -Definitions
It should be noted that other surveillance organizations and researchers may report brain tumors differently from CBTRUS. CBTRUS uses the site definition agreed upon in the Consensus Conference on brain tumor definition and includes lymphoma and other hematopoietic histologies (9590 -9989), and olfactory tumors of the nasal cavity [C30.0 (9522 -9523)] . 13, 14 The definition of brain and CNS tumors used by SEER, NPCR, and NAACCR in their published incidence and mortality statistics is based on the Consensus Conference and, like CBTRUS, includes tumors located in the following sites with their International Classification of Disease, Oncology 3 rd edition (ICD-O-3) 15 site codes in parentheses: brain (C70.0 -9), meninges (C71.0 -9), and other central nervous system tumors (C72.0 -9), but, unlike CBTRUS, excludes lymphoma and leukemia histologies (ICD-O-3 histology codes 9590 -9989) from all brain and CNS sites (Table 1 provides information on included site codes). Leukemias and lymphomas of the brain and CNS are rare, and account for 1% of all brain and CNS tumors from [2008] [2009] [2010] [2011] [2012] . This difference in reporting does not significantly affect rates.
Gliomas are tumors that arise from glial (supportive tissue in the brain) or precursor cells and include astrocytoma, glioblastoma, oligodendroglioma, ependymoma, mixed glioma, malignant glioma, not otherwise specified (NOS), and a few rare histologies. Because there is no standard definition for gliomas, CBTRUS defines glioma as ICD-O-3 histology codes 9380-9384 and 9391-9460 as starred in Tables 2a, 2b and 2c. Additional information on glioma histology categorization is provided in Table 2d . Additionally, CBTRUS reports data on all brain and CNS tumors irrespective of behavior, whereas many reporting organizations may only publish rates for malignant brain and CNS tumors (tumors with an ICD-O-3 behavior code of /3). This policy presents a problem for reporting pilocytic astrocytoma. Pilocytic astrocytoma was assigned an ICD-O-3 15 behavior code of uncertain/1 in 2007 WHO Classification of Tumours of the Central Nervous System. 16, 35 Prior to this classification change, these tumors were historically classified as a malignant tumor, 17 and as a results have been defined as a malignant tumor for the purposes of US cancer registration reporting practices. In keeping with these practices CBTRUS categorizes these tumors as malignant tumors in this report and its other statistical reports.
Caution should be used in comparing incidence rates between statistical reports from different reporting agencies or previous CBTRUS statistical reports due to differences in case definition, data collection, rate calculations, and/or reporting delays.
Methods
Counts, means, rates, ratios, proportions, and other relevant statistics were calculated using R 3. 19,32 Conditional survival is an estimate of the probability that a patient will survive for a specific time period given that they have already survived a certain number of years. For example, 5-year conditional survival for an adolescent (age 15-19 years) who has lived two years since their diagnosis with pilocytic astrocytoma is 98.5%, which means that 98.5% of adolescents who have already survived two years will eventually survive five years.
Results
Cancer is a significant source of morbidity and mortality for adolescents and young adults (age 15-39 years) in the US. Death due to cancer is the fourth most common cause of death overall in this age group (8.78 deaths per 100,000 persons annually) with only accidents (32.95 deaths per 100,000), suicide (12.77 deaths per 100,000), and homicide (10.06 per 100,000) causing more deaths annually in this population between 2008 and 2012. Among all deaths due to cancer by histology, brain and CNS tumors are the 3 rd most common cause of cancer death. Approximately 1.5% of persons will be diagnosed with cancer between the ages of 15 and 39 years, and approximately 0.07% will develop a primary malignant brain tumor.
33
Approximately 10,600 brain and CNS tumors are diagnosed in AYA per year, and they are the cause of approximately 450 deaths annually in this age group.
Comparison to Other Common AYA Cancers
Average annual age-adjusted and crude incidence rates for the five most common cancers in adolescents and young adults (age 15-39 years) are shown in Figure 1A -F. Due to the comparatively low mortality rate that many common cancers have, these may not be the same cancers included for mortality comparison.
thyroid cancer (10.84 per 100,000 population) occurring more frequently. † Primary brain and CNS tumors are the most commonly occurring type of cancer in those age 15-19 years (6.19 per 100,000 population), followed by testes (3.61 per 100,000 male population), Hodgkin lymphoma (3.23 per 100,000 population), leukemia (2.92 per 100,000), and thyroid (2.58 per 100,000 population). † Brain and CNS tumors are the second most commonly occurring cancer in those age 20-24 years (7.12 per 100,000), with only cancer of the testes occurring more frequently (9.43 per 100,000 males). † Brain and CNS tumors are the third most commonly occurring cancer in those age 25-29 years (9.93 per 100,000 population), preceded by cancer of the testes (14.01 per 100,000 male population) and thyroid (10.23 per 100,000 population). † Brain and CNS tumors are the fourth most commonly occurring cancer in those age 30-34 years (12.65 per 100,000 population), preceded by cancer of the breast (27.14 per 100,000 Quinn T. Ostrom: American Brain Tumor Association Adolescent and Young Adult Primary Brain i4 female population), thyroid (15.52 per 100,000 population), and testes (13.84 per 100,000 male population). † Brain and CNS tumors are the third most commonly occurring cancer in those age 35-39 years (15.54 per 100,000 population), preceded by cancer of the breast (60.91 per 100,000 population), and thyroid (18.87 per 100,000 population).
Average annual age-adjusted and crude mortality rates overall and by 5-year age groups for the five most common causes of cancer death in adolescents and young adults are showed in Figure 2A -F. Due to the high mortality caused by cancers with lower incidence, these cancers may be different than those displayed in incidence comparisons. Age ranges for mortality figures reflect age at death, as compared to incidence rates that reflect age at diagnosis. Time period between diagnosis and death can vary substantially by tumor type and by individual. † Primary brain and CNS tumors are the third most common cause of cancer death in those age 15-39 years (1.09 per 100,000 population), with only breast cancer (1.78 per 100,000 female population) and colorectal cancer (1.19 per 100,000 population population) causing a higher rate of deaths. † Primary brain and CNS tumors are the second most common cause of cancer death in persons age 15-19 years (0.49 per 100,000 population in age 15-19 years, 0.56 per 100,000 in Quinn T. Ostrom: American Brain Tumor Association Adolescent and Young Adult Primary Brain
Neuro-Oncology i5 age 20-24 years, and 0.77 per 100,000 population in age 25-29 years), with only leukemia causing more deaths (0.79 per 100,000 in age 15-19 years, 0.97 per 100,000 population in age 20-24 years, and 1.03 per 100,000 population in age 25-29 years). † Primary brain and CNS tumors are the third most common cause of cancer death in persons age 30-39 years (1.11 per 100,000 population in age 30-34 years, and 1.62 per 100,000 population in age 35-39 years). In those age 30-34 years, the more common causes of cancer death are leukemia (1.14 per 100,000 population) and breast cancer (1.36 per 100,000 population), while in those age 35-39 years the more common causes are due to colorectal cancer (2.21 per 100,000 population) and breast cancer (3.36 per 100,000 population).
Overall Incidence by Age Group and Year of Diagnosis
Between 2008 and 2012, 53,083 primary brain and CNS tumors were diagnosed in adolescents and young adults (age 15-39 years) in the US, for a total annual age-adjusted incidence of 10.43 per 100,000 population (Table 3) . Average annual age-adjusted incidence rates of primary brain and CNS tumors and total tumors occurring in the five year period covered in this report are shown in Figure 3 and Table 3 . † Incidence of primary brain and CNS tumors increases with increasing age in those age 15-39 years.
Incidence by Region of the US
Incidence of primary brain and CNS tumors in adolescents and young adults (age 15-39 years) by region of the US is shown in Figure 4a . There are many factors that may affect cancer incidence between different geographic regions including cancer registration practices, and diagnostic practices in addition to true incidence differences. In particular, many central cancer registries vary in their collection of tumors diagnosed only radiographically where persons do not receive surgery, which may have a particularly significant effect on reporting incidence of non-malignant tumors. † Incidence is lowest in New England (9.42 per 100,000 population) and Pacific (9.47 per 100,000 population) regions. † Incidence is highest in Middle Atlantic (11.66 per 100,000 population) and Mountain (11.14 per 100,000 population) regions.
Incidence of malignant primary brain and CNS tumors in adolescents and young adults (age 15-39 years) by region of the US is shown in Figure 4b . (CBTRUS 2008 (CBTRUS -2012 
Incidence by Gender and Age Groups
Average annual incidence rates overall and in adolescents and young adult age groups for males are shown in Table 4 , and for females in Table 5 . † Overall, the incidence of primary brain and CNS tumors in females (12.24 per 100,000 population) is higher than those in males (8.64 per 100,000 population) in AYA. † Incidence rates in persons age 15-19 years are only slightly higher in females (6.83 per 100,000 population) as compared to males (5.58 per 100,000 population), but the difference by gender increases with increasing age.
Incidence rate ratios (IRR) by gender (male:female) for selected histologies in adolescents and young adults (age 15-39 years) are shown in Figure 21 . † There are significant differences in incidence of multiple tumor types by gender in AYA. 
Incidence by Race and Ethnicity
Average annual incidence rates by race for adolescents and young adults (age 15-39 years) are shown in Table 6 . † Overall, AYA incidence is highest in Whites (10.68 per 100,000 population), followed by Blacks (9.42 per 100,000 population), and API (9.37 per 100,000 population). AIAN have the lowest incidence of all racial groups, with average annual age-adjusted incidence of 6.99 per 100,000. † Incidence of tumors of neuroepithelial tissue is higher in whites than in any other racial group in AYA. † Incidence of tumors of the meninges, tumors of the sellar region, and lymphomas and hematopoietic neoplasms are higher in Blacks in the AYA population. † Incidence of tumors of the cranial and spinal nerves and germ cell tumors in AYA have the highest incidence in API.
Incidence rate ratios (IRR) by race (White:Black) in adolescents and young adults (age 15-39 years) for selected histologies are shown in Figure 22 . † There are statistically significant differences in incidence by race in AYA for several histologies. Table 7 . † The overall average annual age-adjusted incidence in nonHispanics (10.86 per 100,000 population) is higher than that of Hispanics (8.70 per 100,000 population). † Incidence of lymphomas and other hematopoietic neoplasms, as well as tumors of the sellar region are slightly more common among Hispanics. (CBTRUS 2008 (CBTRUS -2012 
Incidence by Site and Gender
Average annual age-adjusted incidence rates in AYA by site and gender are shown in Table 11 . † The site with the highest incidence is the pituitary and craniopharyngeal duct (3.30 per 100,000 population) which is more common in females than males followed by the frontal, temporal, parietal, and occipital lobes of the brain (2.08 per 100,000 population) which is more common in males. † The frontal, temporal, parietal, and occipital lobes are the site with the highest incidence in males (2.31 per 100,000 population). † In females, pituitary and craniopharyngeal duct (4.72 per 100,000 population) and the cerebral and spinal meninges (2.51 per 100,000 population) are the sites with the highest incidence.
Relative Survival by Site and Year of Diagnosis
Relative survival rates for malignant tumors by site in AYA are presented in Table 12 . † Five-year relative survival is highest for tumors in the pituitary and craniopharyngeal duct (87.6%), and the cranial nerves (87.6%). † Five-year relative survival is lowest for tumors in the Other nervous system (ICD-O-3 site codes C72.0-C72.9), (41.0%) and the cerebrum (ID-O-3 site code C71.0) (41.3%).
Relative survival rates for malignant tumors by site and 5-year groups in AYA are shown in Table 13 . Relative survival rates have improved significantly over time for all sites. 
Relative Survival by Histologic Group and Year of Diagnosis
Relative survival rates in adolescents and young adults for malignant primary brain and CNS tumors histology are presented in Table 14 . † Five-year relative survival in AYA is highest for pilocytic astrocytoma (93.1%) and malignant ependymal tumors (89.8%). † Five-year relative survival is poorest for glioblastoma (22.5%) and lymphoma (31.5%).
Relative survival rates in adolescents and young adults for malignant brain and CNS tumors by histology and 5-year groups are presented in Table 15 . † Overall, ten-year survival after diagnosis with a malignant brain and CNS tumor has risen from 36.3% in 1973-1977 to 57.6% in 2003-2007 in AYA. † For many histologies, relative survival rates in AYA have not seen large improvements over time.
Relative Survival by Age Group and Histologic Group
Relative survival rates for adolescents and young adults (age 15-39 years) by histology and age group are shown in Table 16 . † Overall, persons age 15-19 years have the highest survival after diagnosis with a malignant brain tumor. Ten-year relative survival in this group is 73.5%, as compared to 44.1% in ages 35-39 years. † A similar trend is seen in most histologies in AYA with the exception of anaplastic astrocytoma and glioblastoma in which there are few differences between age groups.
Relative Survival in Glioma by Age Groups, Sex, Race/ Ethnicity and Insurance Status
Relative survival by sex, race/ethnicity, and insurance status in adolescents and young adults (age 15-39 years) is shown in Figures 24A-24D . † Relative survival rates are highest in younger age groups in AYA and decrease with increasing age. This may be accentuated by the increased incidence of pilocytic astrocytomas in younger age groups, although malignant gliomas show a decrease in survival with increased age at diagnosis as well (Table 16 ). † Females have higher relative survival rates than males in AYA. † White non-Hispanics have the highest survival rates in AYA, although there are not notable differences by race/ethnicity. † Persons with private insurance have the highest rates of relative survival. This is consistent with analyses done on survival in other cancer types, 36 and is likely due a combination of factors that may be associated with insurance status including: geographic access to care, type of health care facility utilized, differences in treatment pattern, and many factors of socioeconomic status. † There is little difference between the relative survival rates of persons with no insurance versus persons with Medicaid in AYA. Previous studies have shown that many people enroll in 
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Medicaid after diagnosis with cancer, which may have been delayed due to prior lack of insurance coverage. 37, 38 This is one potential explanation for the poorer outcomes seen in this group.
Five-Year Conditional Survival after Diagnosis by Selected Histologic Groups
Relative survival provides data on cancer prognosis that is useful at a population level, but these numbers may not be informative for individual patients. In the case of individuals that have already survived a year, or several years after diagnosis with their brain tumor, conditional survival estimates provide information about the likelihood that they will survive into the next period of time. Five-year conditional survival estimates by age group and selected histologies for adolescents and young adults are presented in Figure 25 . † Diagnosis at a younger age in AYA generally led to higher survival rates in all histologies. † For a person age 15-19 years at the time of diagnosis with an astrocytoma, 76.5% survived five years. For those that have already survived two years, 91.0% will go on to survive five years. † For a person age 35-39 years at the time of diagnosis with an astrocytoma, 43.3% survived five years from time of diagnosis. For those that have already survived two years, 68.9% will go on to survive five years.
Time Trends in Incidence of Primary Brain and CNS Tumors in Adolescents and Young Adults
Time trends in cancer incidence rates are an important measure of the changing burden of cancer in a population over time. These time trends are provided for adolescents and young adults in Table 17 Descriptive Summary of Gliomas, Meningioma, and Tumors of the Pituitary in Adolescents and Young Adults.
The data in the American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Descriptive Summary of Meningioma † Meningioma is the second most frequently reported brain and CNS tumor histology, accounting for 15.9% of tumors overall in adolescents and young adults (age 15-39 years) ( Figure 11 ). Quinn T. Ostrom: American Brain Tumor Association Adolescent and Young Adult Primary Brain i18 † Non-malignant meningiomas with ICD-O-3 behavior codes /0 (benign) or /1 (uncertain) account for 79.4% of meningiomas (Table 8) in AYA. † Meningioma is most common in the 35-39 year age group, accounting for 25.1% of tumors, and least common in the 15-19 year age group, accounting for 4.9% of tumors ( Figure 12 ). † Non-malignant meningioma in AYA is 2.5 times more common in females as compared to males (Figure 21 ). † Non-malignant meningioma is 1.1 times more common in
Descriptive Summary of Gliomas
Blacks as compared to Whites in AYA (Figure 22 ). † Ten-year relative survival for malignant meningioma in AYA is 85.6% (Table 14) . 
Descriptive Summary of Tumors of the Pituitary

Risk Factors for Primary Brain and CNS Tumors
Many environmental and behavioral risk factors have been investigated for brain and CNS tumors. The only well-validated factors are increased risk for these tumors (particularly meningiomas) with exposure to ionizing radiation 41 (the type of radiation generated by atomic bombs, therapeutic radiation treatment, CT scans, MRI scans, and X-rays) and decreased risk for these tumors (particularly glioma) in persons with history of allergy or other atopic disease 42 (including eczema, psoriasis, and asthma). Several recent review articles have further elaborated on the current state of risk factor research in primary brain and CNS tumors. Registration of individual cases is conducted by cancer registrars at the institution where diagnosis occurs and is then transmitted to the central cancer registry, which further transmits this information to NPCR or SEER. Central cancer registries (both NPCR and SEER) only report cases to the CDC and NCI for persons that are residents of that particular state, so duplicate records should not occur for persons that may have traveled across state lines for treatment. As a result, the CBTRUS dataset is a complete recording of all cases for the time period examined (with the exception of cases from one registry from 2011-2012) with no duplicates.
No mechanism currently exists for central pathology review of cases within the US cancer registry system, and histology code assignment at case registration is based on histology information contained in the patient's medical record. As a result, histologies are reflective of the prevailing histologic criteria for a histology at the time of registration. This also means that incomplete, incorrect or alternatively stated diagnoses included in a pathology report or other medical record can result in an incorrect reporting of the details of an individual case. For example, an anaplastic oligodendroglioma recorded in a pathology record as oligodendroglioma WHO grade III may be incorrectly recorded as an oligodendroglioma when the accurate category is an anaplastic oligodendroglioma.
Currently, there is no system for the collection of survival and outcomes data from all geographic regions in the US via the cancer registry system. SEER registries are specifically funded to collect active follow-up on patients, and as a result have highly accurate survival data for patients who are diagnosed within the geographic regions covered by these registries. The SEER 18 population dataset used for the survival analyses is a subset of the larger CBTRUS dataset used to generate incidence (99.9% of the US population) 11 and covers approximately 28% of the US population. Survival estimates obtained from the SEER dataset may be less reliable as representations of 'real' relative survival rates for the US than if they were based on data from a larger portion of the population.
Concluding Comment
The American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the US in 2008-2012 comprehensively describes the current population-based incidence of primary malignant and non-malignant brain and other CNS tumors in adolescents and young adults age 15-39 years collected and reported by central cancer registries covering approximately 99.9% of the US population. Despite the significant scientific developments that have occurred in treating cancer in recent years, brain tumors remain a significant source of cancer-related morbidity and mortality in adolescents and young adults. Brain tumor mortality has remained relatively stable, and mortality due to other cancers has not significantly improved. This report aims to provide a level of detail in a comprehensive report that allows for more accurate comparison of the incidence and survival of primary brain and CNS tumors affecting adolescents and young adults, to recognize the impact of these tumors on individuals belonging to this age group and on society overall, and to serve as a useful resource for patients and patient families, surveillance organizations, policy makers, advocates, industry, researchers and clinicians. 9590, 9591, 9596, 9650, 9651, 9652, 9653, 9654, 9655, 9659, 9661, 9662, 9663, 9664, 9665, 9667, 9670, 9671, 9673, 9675, 9680, 9684, 9687, 9690, 9691, 9695, 9698, 9699, 9701, 9702, 9705, 9714, 9719, 9728, 9729 Other hemopoietic neoplasms 9727, 9731, 9733, 9734, 9740, 9741, 9750, 9751, 9752, 9753, 9754, 9755, 9756, 9757, 9758, 9760, 9766, 9823, 9826, 9827, 9832, 9837, 9860, 9861, 9866, 9930 , 9970 Germ Cell Tumors and Cysts Germ cell tumors, cysts and heterotopias 8020, 8440, 9060, 9061, 9064, 9065, 9070, 9071, 9072, 9080, 9081, 9082, 9083, 9084, 9085 53,083 10,617 10.43 (10.34-10.52) 6.19 (6.04-6.34) 7.12 (6.97-7.28) 9.93 (9.73-10.12) 12.65 (12.43-12.88) 15.54 (15.3-15.79) a Annual average cases are calculated by dividing the five-year total by five. b Rates are per 100,000 and are age-adjusted to the 2000 US standard population. c Refers to all brain tumors including histologies not presented in this table.
-Counts are not presented when fewer than 16 cases were reported for the specific histology category. Suppressed cases are included in the total count. Abbreviations: NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified. 30,915 6,183 12.24 (12.10-12.38) 6.83 (6.61-7.06) 8.42 (8.18-8.67) 11.87 (11.57-12.17) 14.93 (14.6-15.28) 18.33 (17.96-18.71) a Annual average cases are calculated by dividing the five-year total by five. b Rates are per 100,000 and are age-adjusted to the 2000 US standard population. c Refers to all brain tumors including histologies not presented in this table.
-Counts are not presented when fewer than 16 cases were reported for the specific histology category. Suppressed cases are included in the total count. Abbreviations: NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified. 41,905 8,381 10.68 (10.58-10.78) 6,936 1,387 9.42 (9.19-9.64) 560 112 6.99 (6.42-7.61) 3,197 639 9.37 (9.04-9.70) The cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases. The cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases. Rates are an estimate of the percentage of patients alive at one, two, three, four, five, and ten year, respectively. c Estimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence -SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (1973 -2012 
